Elite Pharmaceuticals Q1 Earnings Call Highlights

Elite Pharmaceuticals reported fiscal Q1 2027 revenue of $32.4 million and operating profit of $7.5 million, broadly consistent with the prior three quarters. Operating cash flow was $10.1 million, while cash increased to $38.9 million.

Overall volume rose 14.75% year over year, with lisdexamfetamine volume up 10% and market share increasing 10.2% despite normalized pricing.

New launches and pipeline progress included methadone, buprenorphine, an anticonvulsant candidate and an anticoagulant potentially targeted for a 2028 launch.

Elite is evaluating a Nasdaq uplisting and potential buyout, while planning manufacturing-capacity expansion.

The company is also assessing alternatives for warrants expiring in April 2027 and expects to resolve them before expiration.

Elite Pharmaceuticals OTCMKTS: ELTP reported first-quarter fiscal 2027 revenue of $32.4 million and operating profit of $7.5 million, with Chief Financial Officer Carter Ward describing both measures as steady and consistent with the preceding three quarters.

The quarter ended June 30, 2026, and Elite’s fiscal year ends March 31.

Ward said comparisons with the prior-year quarter require context because the June 2025 period was the company’s strongest quarter to date, benefiting from the early stages of the generic lisdexamfetamine market, the generic version of Vyvanse.

“Revenues for the quarter were $32.4 million and operating profits were $7.5 million, both in line with the previous three quarters, both solid and steady,” Ward said.

Ward said Elite launched generic lisdexamfetamine in early 2025, entering a market that initially had relatively high prices but also drew more than 10 competing companies.

As competition increased, prices declined before the market reached what he characterized as a more stable equilibrium.

According to Ward, Elite has maintained and increased its market share in lisdexamfetamine while prices, volumes and operations have stabilized.

He said the company is now an established supplier of generic Vyvanse, similar to its longstanding position in generic Adderall products.

Chief Executive Officer Nasrat Hakim said overall volume increased 14.75% year over year during the quarter.

He said lisdexamfetamine volume rose 10%, while market share increased 10.2% despite the price normalization following the initial generic launch.

Hakim said Elite’s four largest products—lisdexamfetamine, mixed amphetamine immediate-release, amphetamine extended-release and naltrexone—have gained market share while maintaining prices.

Sales of legacy products including isradipine, trimipramine, trandolapril and phentermine were in line with previous years, he said.

Ward also addressed higher cost of goods sold, saying volume growth contributes to higher costs and that the sales mix has changed.

Naltrexone, which Elite was not selling in the comparable prior-year period, uses an expensive active ingredient and has added to cost of goods sold, he said.

Elite’s largest customer accounted for 60% of revenue, compared with 51% a year earlier.

Ward said the generic-drug market is broadly concentrated among a small number of large wholesalers, but he attributed lisdexamfetamine price changes to supply, demand and industry competition rather than customer concentration or price concessions from a particular customer.

Cash provided by operations was $10.1 million in the quarter, compared with $14.8 million in the year-earlier period.